SCHEMBL4294149

SCHEMBL4294149

O=Cc1ccncc1-c1cc(Cl)ccc1C=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
ERN1 O75460 2/20 0.42
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE2A O00408 2/20 0.38
PDE10A Q9Y233 2/20 0.38
IDO1 P14902 1/20 0.38
CDC25B P30305 1/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 1/20 0.38
CHUK O15111 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 2/20 0.35
XDH P47989 1/20 0.35
HPGD P15428 1/20 0.35
ORAI1 Q96D31 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19126830 0.81 SLC22A12 (0.44) TDP1ERN1KDM4EALDH1A1SMN1; SMN2
SCHEMBL6710790 0.79 ERN1 (0.54) TDP1ERN1KDM4EALDH1A1LMNA
SCHEMBL1769942 0.76 PDE2A (0.48) KDM4EALDH1A1SMN1; SMN2PDE2APDE10A
SCHEMBL29681568 0.76 CCNT1 (0.42) ERN1CCNT1CDK9HASPIN
SCHEMBL6930919 0.74 TDP1 (0.55) TDP1ERN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL13659537 0.74 MAOA (0.48) TDP1ERN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL24637251 0.74 TDO2 (0.39) TDP1ERN1KDM4EIDO1
SCHEMBL15652488 0.73 SLC22A12 (0.48) ERN1ALDH1A1
SCHEMBL19153597 0.72 TDP1 (0.57) TDP1ERN1KDM4EALDH1A1SMN1; SMN2
SCHEMBL10041665 0.71 TDP1 (0.57) TDP1ERN1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A TDP1 711/4885ERN1 1611/4885KDM4E 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.